利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

221 条记录 (耗时 0.055 秒)

    T CELL RECEPTORS RECOGNIZING HLA-A1- OR HLA-CW7-RESTRICTED MAGE
    32.
    发明申请
    T CELL RECEPTORS RECOGNIZING HLA-A1- OR HLA-CW7-RESTRICTED MAGE 审中-公开
    T细胞受体识别HLA-A1-或HLA-CW7限制性MAGE

    公开(公告)号：US20140378389A1

    公开(公告)日：2014-12-25

    申请号：US14344354

    申请日：2012-09-11

    申请人： The United States of America, as represented by the Secretary, Dept. of Health and Human Services

    发明人： Paul F. Robbins ,  Steven A. Rosenberg ,  Shiqui Zhu ,  Steven A. Feldman ,  Richard A. Morgan

    IPC分类号： C07K14/705 ,  G01N33/574 ,  C07K16/28

    摘要： The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for a) melanoma antigen family A (MAGE A)-3 in the context of HLA-A1 or b) MAGE-A12 in the context of HLA-Cw7. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are further provided by the invention.

    摘要翻译： 本发明提供了在HLA-A1或b）MAGE-A12在HLA-Cw7的上下文中对a）黑素瘤抗原家族A（MAGE A）-3具有抗原特异性的分离或纯化的T细胞受体（TCR）。 本发明还提供了相关的多肽和蛋白质，以及相关的核酸，重组表达载体，宿主细胞和细胞群。 本发明进一步提供的是抗体或其抗原结合部分，以及与本发明的TCR有关的药物组合物。 通过本发明进一步提供了检测宿主中癌症存在的方法以及在宿主中治疗或预防癌症的方法。

    METHOD FOR THE DIAGNOSIS OF AGE-ASSOCIATED VASCULAR DISORDERS
    36.
    发明申请
    METHOD FOR THE DIAGNOSIS OF AGE-ASSOCIATED VASCULAR DISORDERS 审中-公开
    用于诊断与年龄相关的血管疾病的方法

    公开(公告)号：US20120004133A1

    公开(公告)日：2012-01-05

    申请号：US13202319

    申请日：2010-02-19

    申请人： Mingyi Wang ,  Zongming Fu ,  Edward G. Lakatta ,  Jennifer Van Eyk

    发明人： Mingyi Wang ,  Zongming Fu ,  Edward G. Lakatta ,  Jennifer Van Eyk

    IPC分类号： C40B30/04 ,  G01N33/53 ,  G01N27/447 ,  C12Q1/68

    CPC分类号： G01N33/6893 ,  G01N2333/485 ,  G01N2800/32 ,  G01N2800/323 ,  G01N2800/324 ,  G01N2800/325

    摘要： Methods for determining if a subject has or is susceptible to having an age-associated vascular disorder are disclosed. The method includes determining if the subject exhibits altered expression of a product of one or more of the genes listed in Table 1 relative to a control level of expression of the gene product. Altered expression of one or more of the genes listed in Table 1 indicates that the subject has or is susceptible to having an age-associated vascular disorder. In specific examples the gene product is a product of the MFG-E8 and an increase in expression indicates the subject has or is susceptible to having an age-associated vascular disorder.

    摘要翻译： 公开了确定受试者是否具有或具有年龄相关性血管疾病的方法。 该方法包括确定受试者是否表现出相对于基因产物的表达的对照水平，表1中列出的一种或多种基因的产物的表达改变。 表1中列出的一种或多种基因的改变的表达表明受试者具有或易患有年龄相关的血管疾病。 在具体实例中，基因产物是MFG-E8的产物，并且表达增加表示受试者具有或易于患有年龄相关的血管疾病。

    RADIOLABELED AFFIBODY MOLECULES
    37.
    发明申请
    RADIOLABELED AFFIBODY MOLECULES 有权
    放射性AFFIBODY分子

    公开(公告)号：US20100254899A1

    公开(公告)日：2010-10-07

    申请号：US12528823

    申请日：2008-02-27

    申请人： Jacek Capala ,  Dale O. Kiesewetter ,  Gabriela Kramer-Marek ,  Sang Bong Lee

    发明人： Jacek Capala ,  Dale O. Kiesewetter ,  Gabriela Kramer-Marek ,  Sang Bong Lee

    IPC分类号： A61K51/10 ,  C07K16/00 ,  A61P19/04

    CPC分类号： A61K51/1045 ,  C07K14/31

    摘要： The invention provides a radiolabeled affibody molecule comprising a fragment of an IgG-binding domain of protein A from Staphylococcus aureus, a bifunctional linker, and a radiolabel comprising 18F or 76Br, wherein the bifunctional linker links the fragment and the radiolabel. The affibody molecule binds with high affinity to select receptors, which are over-expressed in certain cancers. Since the radionuclides emit a positron, the in vitro and in vivo binding characteristics of the radiolabeled affibody can be assessed using diagnostic imaging.

    摘要翻译： 本发明提供了放射性标记的亲和体分子，其包含来自金黄色葡萄球菌的蛋白A的IgG结合结构域的片段，双功能接头和包含18F或76Br的放射性标记，其中所述双功能连接体连接片段和放射性标记。 亲和子分子以高亲和力结合选择在某些癌症中过表达的受体。 由于放射性核素发射正电子，所以可以使用诊断成像来评估放射性标记亲和体的体外和体内结合特征。

    DELETION OF THE BETA 20-21 LOOP IN HIV GP120 EXPOSES THE CD4 BINDING SITE FOR IMPROVED ANTIBODY BINDING AND ANTIBODY INDUCTION
    38.
    发明申请
    DELETION OF THE BETA 20-21 LOOP IN HIV GP120 EXPOSES THE CD4 BINDING SITE FOR IMPROVED ANTIBODY BINDING AND ANTIBODY INDUCTION 有权
    艾滋病毒GP120中的20-21环的删除暴露了用于改善抗体结合和抗体诱导的CD4绑定位点

    公开(公告)号：US20100215682A1

    公开(公告)日：2010-08-26

    申请号：US12714085

    申请日：2010-02-26

    申请人： Ira Berkower

    发明人： Ira Berkower

    IPC分类号： A61K39/29 ,  C07K14/00 ,  C07H21/00 ,  C12N15/74 ,  C12N5/10 ,  A61K39/00 ,  C12N7/00 ,  A61P31/18 ,  A61P37/04

    CPC分类号： C07K14/005 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/5258 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/55561 ,  A61K2039/6075 ,  C07K16/1063 ,  C07K2317/76 ,  C12N2740/16122 ,  C12N2740/16134

    摘要： Disclosed herein are isolated immunogens including variant gp120 polypeptides. In an example, a variant gp120 polypeptide includes a deletion of at least 8 consecutive residues of the fourth conserved loop (C4) between residues 419 and 434 of gp120 according to HXB2 numbering. Also provided are isolated nucleic acid molecules encoding the disclosed isolated immunogens. In an example, an isolated nucleic acid molecule further includes a nucleic acid molecule encoding a hepatitis B surface antigen or a variant thereof. Compositions including the isolated immunogens including variant gp120 polypeptides are also disclosed. In some examples, a composition further includes a carrier protein, such as a hepatitis B surface antigen or a variant thereof (natural or recombinant). Viral-like particles are also provided including any of the disclosed isolated immunogens or compositions. Also disclosed are uses of these variant gp120 polypeptides and nucleic acids encoding variant polypeptides, such as to induce an immune response to HIV-1.

    摘要翻译： 本文公开了分离的免疫原，包括变体gp120多肽。 在一个实例中，变体gp120多肽包括根据HXB2编号在gp120的残基419和434之间的第四个保守环（C4）的至少8个连续残基的缺失。 还提供了编码公开的分离的免疫原的分离的核酸分子。 在一个实例中，分离的核酸分子还包括编码乙型肝炎表面抗原或其变体的核酸分子。 还公开了包括分离的免疫原的组合物，包括变体gp120多肽。 在一些实例中，组合物还包括载体蛋白，例如乙型肝炎表面抗原或其变体（天然或重组）。 还提供病毒样颗粒，包括任何公开的分离的免疫原或组合物。 还公开了这些变体gp120多肽和编码变体多肽的核酸的用途，例如诱导对HIV-1的免疫应答。

    METHOD OF PREPARING MACROMOLECULAR CONTRAST AGENTS AND USES THEREOF
    40.
    发明申请
    METHOD OF PREPARING MACROMOLECULAR CONTRAST AGENTS AND USES THEREOF 有权
    制备大分子对比剂的方法及其用途

    公开(公告)号：US20100056776A1

    公开(公告)日：2010-03-04

    申请号：US12513813

    申请日：2007-11-06

    申请人： Martin W. Brechbiel ,  Heng Xu

    发明人： Martin W. Brechbiel ,  Heng Xu

    IPC分类号： C07D403/12 ,  C07C229/00 ,  C07D207/46 ,  C07D207/40 ,  C07D257/02

    CPC分类号： A61K51/065 ,  A61K47/59 ,  A61K47/595 ,  A61K49/085 ,  A61K49/124

    摘要： Disclosed are methods of preparing a macromolecular conjugated ligand and a metal complex thereof. The metal complex is targeted for use as a contrast agent, for example, in MRI. The method of preparing a macromolecular conjugated ligand comprises: (a) providing a compound of formula (I) wherein R, A, and Pg are as defined herein, (b) reacting the compound of formula (I) with a macromolecular compound (e.g., dendrimer) in an organic solvent medium which is substantially free of water to obtain a macromolecular conjugated compound, and (c) removing the carboxyl-protecting groups to obtain a carboxyl-deprotected macromolecular conjugated compound. The metal complex can be prepared by reacting the carboxyl-deprotected macromolecular conjugated compound with an ion (e.g., Gd(III)). Also disclosed are two carboxyl-protected 1B4M-DTPA intermediate compounds.

    摘要翻译： 公开了制备大分子共轭配体及其金属络合物的方法。 金属络合物被靶向用作造影剂，例如在MRI中。 制备大分子缀合配体的方法包括：（a）提供其中R，A和Pg如本文所定义的式（I）化合物，（b）使式（I）化合物与高分子化合物 树枝状大分子）在基本上不含水的有机溶剂介质中，得到高分子共轭化合物，（c）除去羧基保护基，得到羧基脱保护的高分子共轭化合物。 金属络合物可以通过羧基脱保护的大分子共轭化合物与离子（例如Gd（III））反应来制备。 还公开了两种羧基保护的1B4M-DTPA中间体化合物。